Skip to content
Subscriber Only

Valeant Executive Who Led Female Libido Pill Unit Is Out

  • Sprout CEO Whitehead out after less than three months
  • Drugmaker paid $1 billion to acquire sexual desire drug
Video player cover image

The Road Ahead for Addyi: Why Did Sprout's CEO Leave?

Updated on

The head of Sprout Pharmaceuticals, the women’s libido pill maker that Valeant Pharmaceuticals International Inc. bought for $1 billion, is leaving less than three months after her company was folded into the larger drugmaker.

Cindy Whitehead, chief executive officer at Sprout, had initially promised to stay at Valeant and help build the team that would sell Addyi, used to treat low sex drive in women. Women’s health experts have questioned the pill’s effectiveness and side effects. The drug hasn’t sold well in its first weeks on the market, moving only a few hundred prescriptions in the U.S., according to data from Bloomberg Intelligence.